Most Read Articles
Pearl Toh, 5 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Yesterday
Nocturia is a risk factor for mortality, according to the results of the Nagahama Study, which boasts of a low incidence of missing data and high representation of the general population.
Audrey Abella, 14 Oct 2020
Despite a 90-percent cure rate after first treatment for children with acute lymphoblastic leukaemia (ALL), approximately 10–15 percent of patients with paediatric ALL will experience relapse. [Expert Rev Anticancer Ther 2017;17:725-736] A recent webinar on the current landscape of ALL highlighted the potential of immunotherapy for paediatric patients with relapsed or refractory ALL, thus providing hope for this high-risk patient group.

Men with SLE at increased risk of coronary artery calcifications

05 Jun 2018
Stem cells have been found to be responsible for calcification in arteries of patients with chronic kidney disease

Men with systemic lupus erythematosus (SLE) are more likely to develop coronary artery calcifications (CAC) than age- and sex-matched controls, a recent study has shown. Such risk among patients with SLE is associated with older age, increasing chronic damage and cumulative dose of corticosteroids.

CAC occurred more frequently in patients with SLE than in controls (18 percent vs 7 percent; odds ratio [OR], 2.89; 95 percent CI, 1.07–8.65). The following factors independently correlated with the presence of calcifications: age (OR, 1.12; 1.04–1.20), SLE diagnosis (OR, 3.38; 1.07–10.64), diabetes mellitus (OR, 6.88; 1.50–31.62), Framingham risk score (OR, 1.12; 1.00–1.23) and glomerular filtration rate (OR, 0.98; 0.96–1.00).

Patients with SLE presented with CAC starting at age 32 years, within 2.3 years of diagnosis. The following were independent risk factors for CAC: increasing age (OR, 1.18; 1.06–1.31), Systemic Lupus International Collaborating Clinics score (OR, 2.85; 1.21–6.73) and cumulative dose of prednisone (OR, 1.04; 1.01–1.08).

To determine whether the prevalence and extent of asymptomatic coronary artery atherosclerosis were increased in men with SLE vs controls, the investigators used multidetector computed tomography to screen 95 patients with SLE (mean age 34.7 years) and 100 control participants (mean age 34.8 years) with no history of coronary artery disease for CAC. The Agatston score was used to measure the extent of calcification.

The investigators compared the frequency of risk factors between patients and controls, and examined the relationship between clinical and immunological characteristics and the presence of CAC.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 5 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Yesterday
Nocturia is a risk factor for mortality, according to the results of the Nagahama Study, which boasts of a low incidence of missing data and high representation of the general population.
Audrey Abella, 14 Oct 2020
Despite a 90-percent cure rate after first treatment for children with acute lymphoblastic leukaemia (ALL), approximately 10–15 percent of patients with paediatric ALL will experience relapse. [Expert Rev Anticancer Ther 2017;17:725-736] A recent webinar on the current landscape of ALL highlighted the potential of immunotherapy for paediatric patients with relapsed or refractory ALL, thus providing hope for this high-risk patient group.